文献速递MDS 与骨髓增殖性肿瘤

世界卫生组织定义的嗜酸性粒细胞疾病:2019年诊断、风险分层与管理更新

World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
PubMed 文献 · Am J Hematol · 2019-01-01

本文综述了嗜酸性粒细胞疾病的诊断、风险分层和治疗。嗜酸性粒细胞增多症定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L,需排除继发原因后评估原发疾病。2016年WHO分类包括伴PDGFRA、PDGFRB、FGFR1重排或PCM1-JAK2的髓系/淋系肿瘤伴嗜酸性粒细胞增多症,以及CEL,NOS等。治疗目标是减轻嗜酸性粒细胞介导的器官损伤,PDGFRA重排者对伊马替尼敏感。

要点

  • 嗜酸性粒细胞增多症定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L。
  • 诊断原发嗜酸性粒细胞疾病需结合形态学、细胞遗传学、FISH、流式免疫表型和T细胞克隆性评估。
  • 伴PDGFRA或PDGFRB重排的疾病对伊马替尼敏感,识别重排至关重要。

核心结论

  • 嗜酸性粒细胞疾病涵盖继发性和原发性克隆性 disorders,诊断需排除继发原因并识别分子亚型以指导风险适应治疗。

研究设计与样本

  • 综述,基于2016年WHO分类的半分子分类方案更新诊断、风险分层和管理。

主要发现

  • 嗜酸性粒细胞增多症通常定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L,可能伴有组织损伤。
  • 2016年WHO分类包括主要类别「伴PDGFRA、PDGFRB或FGFR1重排或伴PCM1-JAK2的髓系/淋系肿瘤伴嗜酸性粒细胞增多症」和MPN亚型「慢性嗜酸性粒细胞白血病,非特指型」(CEL,NOS)。
  • 淋巴细胞变异型嗜酸性粒细胞增多症是异常T细胞克隆驱动的反应性嗜酸性粒细胞增多,特发性嗜酸性粒细胞增多综合征(HES)是排除性诊断。

关键数值与推荐

  • 对于较轻型嗜酸性粒细胞增多(如小于1.5×10^9/L)无器官受累症状或体征的患者,可采取观察等待和密切随访。
  • 识别PDGFRA或PDGFRB重排至关重要,因为这些疾病对伊马替尼极度敏感。
  • 皮质类固醇是淋巴细胞变异型嗜酸性粒细胞增多症和HES的一线治疗。
  • 羟基脲和干扰素-α已证明作为HES的初始治疗和类固醇难治病例的有效性。

临床怎么用

  • 对嗜酸性粒细胞增多患者,先排除继发原因,再进行形态学、细胞遗传学、FISH、流式免疫表型和T细胞克隆性评估以识别克隆性标志。
  • 检测PDGFRA或PDGFRB重排以指导伊马替尼治疗。
  • 根据疾病亚型和严重程度选择观察等待、皮质类固醇、羟基脲、干扰素-α或针对IL-5的抗体等治疗。

局限性

  • 第二线细胞毒性化疗和造血干细胞移植用于侵袭性HES和CEL的结局仅来自有限数量患者。
  • 抗IL-5抗体(美泊利单抗)、抗IL-5受体抗体(贝那利珠单抗)及其他嗜酸性粒细胞靶点的使用仍处于活跃研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. DIAGNOSIS: Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109 /L, and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of various tests. They include morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ-hybridization, flow immunophenotyping, and T-cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic hematolymphoid neoplasm. RISK STRATIFICATION: Disease prognosis relies on identifying the subtype of eosinophilia. After evaluation of secondary causes of eosinophilia, the 2016 World Health Organization endorses a semi-molecular classification scheme of disease subtypes. This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2", and the MPN subtype, "chronic eosinophilic leukemia, not otherwise specified" (CEL, NOS). Lymphocyte-variant hypereosinophilia is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. RISK-ADAPTED THERAPY: The goal of therapy is to mitigate eosinophil-mediated organ damage. For patients with milder forms of eosinophilia (eg, <1.5 × 109 /L) without symptoms or signs of organ involvement, a watch and wait approach with close-follow-up may be undertaken. Identification of rearranged PDGFRA or PDGFRB is critical because of the exquisite responsiveness of these diseases to imatinib. Corticosteroids are first-line therapy for patients with lymphocyte-variant hypereosinophilia and HES. Hydroxyurea and interferon-alfa have demonstrated efficacy as initial treatment and in steroid-refractory cases of HES. In addition to hydroxyurea, second line cytotoxic chemotherapy agents, and hematopoietic stem cell transplantation have been used for aggressive forms of HES and CEL, with outcomes reported for limited numbers of patients. The use of antibodies against interleukin-5 (IL-5) (mepolizumab), the IL-5 receptor (benralizumab), as well as other targets on eosinophils remains an active area of investigation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019. PMID: 31423623. doi:10.1002/ajh.25617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。